Multi-targeted tyrosine kinase inhibitors in clinical development: Focus on XL-184 (cabozantinib)

Drugs of Today

Volumn 47, Issue 11, 2011, Pages 857-868

  Bowles, D W ^a   Kessler, E R ^a   Jimeno, Antonio ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMUVATINIB; E 7050; ERLOTINIB; FORETINIB; MGCD 265; PROTEIN RET; ROSIGLITAZONE; SCATTER FACTOR RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 2; XL 184;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BONE METASTASIS; CONVULSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG WITHDRAWAL; FATIGUE; GLIOBLASTOMA; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; THYROID CARCINOMA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 83255186301     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.11.1688487     Document Type: Review

References (85)

1. Sonnenberg, E., Meyer, D., Weidner, K.M., Birchmeier, C. Scatter factor/hepatocyte growth factor and its receptor, the c-Met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 1993, 123(1): 223-35. (Pubitemid 23284877)
2. Machide, M., Hashigasako, A., Matsumoto, K., Nakamura, T. Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J Biol Chem 2006, 281(13): 8765-72. (Pubitemid 43847982)
3. Ponzetto, C., Bardelli, A., Zhen, Z. et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77(2): 261-71. (Pubitemid 24138623)
4. Palka, H.L., Park, M., Tonks, N.K. Hepatocyte growth factor receptor tyrosine kinase Met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J Biol Chem 2003, 278(8): 5728-35. (Pubitemid 36800817)
5. Baselga, J., De Jonge, M.J., Rodon, J. et al. A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 3003.
6. Trusolino, L., Bertotti, A., Comoglio, P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010, 11(12): 834-48.
7. Pelicci, G., Giordano, S., Zhen, Z. et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 1995, 10(8): 1631-8.
8. Zhang, Y.W., Wang, L.M., Jove, R., Vande Woude, G.F. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 2002, 21(2): 217-26. (Pubitemid 34102130)
9. Birchmeier, C., Birchmeier, W., Gherardi, E., Vande Woude, G.F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4(12): 915-25. (Pubitemid 37493640)
10. Birchmeier, C., Gherardi, E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998, 8(10): 404-10. (Pubitemid 28458706)
11. Michalopoulos, G.K., DeFrances, M.C. Liver regeneration. Science 1997, 276(5309): 60-6.
12. Bottaro, D.P., Rubin, J.S., Faletto, D.L., Chan, A.M., Kmiecik, T.E., Vande Woude, G.F., Aaronson, S.A. Identification of the hepatocyte growth factor receptor as the c-Met proto-oncogene product. Science 1991, 251(4995): 802-4. (Pubitemid 21926175)
13. Nakamura, T., Nishizawa, T., Hagiya, M. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342(6248): 440-3. (Pubitemid 19277521)
14. Comoglio, P.M., Giordano, S., Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008, 7(6): 504-16. (Pubitemid 351767118)
15. Camp, R.L., Rimm, E.B., Rimm, D.L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86(11): 2259-65. (Pubitemid 30010366)
16. Di Renzo, M.F., Olivero, M., Giacomini, A. et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995, 1(2): 147-54.
17. Morello, S., Olivero, M., Aimetti, M., Bernardi, M., Berrone, S., Di Renzo, M.F., Giordano, S. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol 2001, 189(3): 285-90. (Pubitemid 33063296)
18. Di Renzo, M.F., Poulsom, R., Olivero, M., Comoglio, P.M., Lemoine, N.R. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995, 55(5): 1129-38.
19. Humphrey, P.A., Zhu, X., Zarnegar, R., Swanson, P.E., Ratliff, T.L., Vollmer, R.T., Day, M.L. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995, 147(2): 386-96.
20. Natali, P.G., Prat, M., Nicotra, M.R., Bigotti, A., Olivero, M., Comoglio, P.M., Di Renzo, M.F. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 1996, 69(3): 212-7. (Pubitemid 26233301)
21. Ruco, L.P., Ranalli, T., Marzullo, A., Bianco, P., Prat, M., Comoglio, P.M., Baroni, C.D. Expression of Met protein in thyroid tumours. J Pathol 1996, 180(3): 266-70. (Pubitemid 26393674)
22. Miller, C.T., Lin, L., Casper, A.M. et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006, 25(3): 409-18. (Pubitemid 43117626)
23. Hara, T., Ooi, A., Kobayashi, M., Mai, M., Yanagihara, K., Nakanishi, I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998, 78(9): 1143-53. (Pubitemid 28440830)
24. Bean, J., Brennan, C., Shih, J.Y. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104(52): 20932-7.
25. Di Renzo, M.F., Olivero, M., Martone, T. et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000, 19(12): 1547-55. (Pubitemid 30175676)
26. Schmidt, L., Duh, F.M., Chen, F. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 1997, 16(1): 68-73. (Pubitemid 27198158)
27. Mantripragada, K.K., Spurlock, G., Kluwe, L. et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res 2008, 14(4): 1015-24. (Pubitemid 351302546)
28. Previdi, S., Maroni, P., Matteucci, E., Broggini, M., Bendinelli, P., Desiderio, M.A. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer 2010, 46(9): 1679-91.
29. Stella, G.M., Benvenuti, S., Comoglio, P.M. Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drugs 2010, 19(11): 1381-94.
30. Carmeliet, P., Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801): 249-57.
31. Carmeliet, P., Jain, R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011, 10(6): 417-27.
32. Carmeliet, P., Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473(7347): 298-307.
33. De Bock, K., Mazzone, M., Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011, 8(7): 393-404.
34. Laramee, M., Chabot, C., Cloutier, M., Stenne, R., Holgado-Madruga, M., Wong, A.J., Royal, I. The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation. J Biol Chem 2007, 282(11): 7758-69. (Pubitemid 47093597)
35. Gerber, H.P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B.A., Dixit, V., Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273(46): 30336-43. (Pubitemid 28545503)
36. Takahashi, T., Yamaguchi, S., Chida, K., Shibuya, M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001, 20(11): 2768-78. (Pubitemid 32938560)
37. Lamalice, L., Houle, F., Jourdan, G., Huot, J. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 2004, 23(2): 434-45. (Pubitemid 38174998)
38. Somanath, P.R., Malinin, N.L., Byzova, T.V. Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 2009, 12(2): 177-85.
39. Fuh, G., Li, B., Crowley, C., Cunningham, B., Wells, J.A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 1998, 273(18): 11197-204. (Pubitemid 28204970)
40. Charpidou, A., Gkiozos, I., Konstantinou, M. et al. Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients. Cancer Lett 2011, 304(2): 144-53.
41. Farace, F., Gross-Goupil, M., Tournay, E. et al. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer 2011, 104(7): 1144-50.
42. Linderholm, B.K., Hellborg, H., Johansson, U., Skoog, L., Lehtio, J. Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer. Breast Cancer Res Treat 2011, 125(2): 457-65.
43. Carrillo de Santa Pau, E., Arias, F.C., Caso Pelaez, E. et al. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 2009, 115(8): 1701-12.
44. Kim, D.H., Xu, W., Kamel-Reid, S., Liu, X., Jung, C.W., Kim, S., Lipton, J.H. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol 2010, 21(6): 1179-88.
45. Duignan, I.J., Corcoran, E., Pennello, A. et al. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models. Neoplasia 2011, 13(1): 49-59.
46. Roland, C.L., Dineen, S.P., Lynn, K.D. et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009, 8(7): 1761-71.
47. Brekken, R.A., Overholser, J.P., Stastny, V.A., Waltenberger, J., Minna, J.D., Thorpe, P.E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000, 60(18): 5117-24.
48. Fusco, A., Grieco, M., Santoro, M. et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987, 328(6126): 170-2. (Pubitemid 17108219)
49. Wells, S.A., Jr., Santoro, M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res 2009, 15(23): 7119-23.
50. Phay, J.E., Shah, M.H. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010, 16(24): 5936-41.
51. Hasegawa, T., Enomoto, A., Kato, T. et al. Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice. Oncogene 2008, 27(43): 5684-95.
52. Besset, V., Scott, R.P., Ibanez, C.F. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem 2000, 275(50): 39159-66. (Pubitemid 32058932)
53. Panta, G.R., Du, L., Nwariaku, F.E., Kim, L.T. Direct phosphorylation of proliferative and survival pathway proteins by RET. Surgery 2005, 138(2): 269-74. (Pubitemid 41253810)
54. Arighi, E., Borrello, M.G., Sariola, H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005, 16(4-5): 441-67. (Pubitemid 41022013)
55. Edery, P., Lyonnet, S., Mulligan, L.M. et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367(6461): 378-80. (Pubitemid 24062346)
56. Romeo, G., Ronchetto, P., Luo, Y. et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367(6461): 377-8.
57. Mulligan, L.M., Kwok, J.B., Healey, C.S. et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363(6428): 458-60. (Pubitemid 23179393)
58. Hofstra, R.M., Landsvater, R.M., Ceccherini, I. et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367(6461): 375-6.
59. Papotti, M., Olivero, M., Volante, M., Negro, F., Prat, M., Comoglio, P.M., DiRenzo, M.F. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 2000, 11(1): 19-30. (Pubitemid 30307941)
60. Komminoth, P., Roth, J., Muletta-Feurer, S., Saremaslani, P., Seelentag, W.K., Heitz, P.U. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1996, 81(6): 2041-6. (Pubitemid 26175924)
61. Sawai, H., Okada, Y., Kazanjian, K. et al. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 2005, 65(24): 11536-44. (Pubitemid 41821712)
62. Moses, W., Weng, J., Kebebew, E. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid 2011, 21(4): 367-71.
63. Wells, S.A., Jr., Gosnell, J.E., Gagel, R.F. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010, 28(5): 767-72.
64. Wells, S.A., Robinson, B.G., Gagel, R.F. et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 5503.
65. Qian, F., Engst, S., Yamaguchi, K. et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009, 69(20): 8009-16.
66. Eder, J.P., Shapiro, G.I., Appleman, L.J. et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010, 16(13): 3507-16.
67. Drouin, M.A., Kollmannsberger, C.K., Uronis, H.E. et al. Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101). J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 3106.
68. Heath, E.I., LoRusso, P., Kurzrock, R. et al. A phase I study of oral administration of MGCD265 in patients with advanced malignancies (study 265-102). J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 3108.
69. Nakagawa, T., Tohyama, O., Yamaguchi, A. et al. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 2010, 101(1): 210-5.
70. Welsh, J.W., Mahadevan, D., Ellsworth, R., Cooke, L., Bearss, D., Stea, B. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 2009, 4: 69.
71. You, W.K., Sennino, B., Williamson, C.W. et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011, 71(14): 4758-68.
72. Su, W., Gutmann, D.H., Perry, A., Abounader, R., Laterra, J., Sherman, L.S. CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia 2004, 45(3): 297-306. (Pubitemid 38222258)
73. Torres, K.E., Zhu, Q.S., Bill, K. et al. Activated MET Is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 2011, 17(12): 3943-55.
74. Exelixis, Inc. Cabozantinib. http://www.exelixis.com/cabozantinib/ preclinical-rationale-results/active-agent. Accessed August 4, 2011.
75. Kurzrock, R., Sherman, S.I., Ball, D.W. et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011, 29(19): 2660-6.
76. Choueiri, T.K., Pal, S.K., Cabanillas, M.E. et al. Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC). J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(7, Suppl.): Abst e13042.
77. Buckanovich, R.J., Berger, Sella, A. et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(7, Suppl.): Abst 5008.
78. Gordon, M.S., Vogelzang, N.J., Schoffski, P. et al. Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(7, Suppl.): Abst 3010.
79. Wen, P.Y., Prados, M., Schiff, D. et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 2006.
80. Wakelee, H.A., Gettinger, S.N., Engelman, J.A. et al. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 3017.
81. Chow, H., Jung, A., Talbott, J., Lin, A.M., Daud, A.I., Coakley, F.V. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr 2011, 35(1): 86-90.
82. Hussain, M., Smith, U.N., Sweeney, C. et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(7, Suppl.): Abst 4516.
83. Previdi, S., Abbadessa, G., Dalo, F., France, D.S., Broggini, M. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther 2011.
84. Zhang, S., Zhau, H.E., Osunkoya, A.O. et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1- dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 2010, 9: 9.
85. Sampson, E.R., Martin, B.A., Morris, A.E., Xie, C., Schwarz, E.M., O'Keefe, R.J., Rosier, R.N. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res 2011, 26(6): 1283-94.